OAK BROOK, Ill. — Breast cancer screening with MRI can detect invasive cancers missed on mammography in women who’ve undergone chest irradiation for other diseases, according to a new study published online and in the April print edition of Radiol…
Three of the world’s top lung associations have published a new international multidisciplinary classification of lung adenocarcinoma, the first revision to the classification in six years.
The new classification is published in the February editi…
Time constraints, other illnesses and patient embarrassment may prevent dermatologists, internists and family practitioners from conducting full-body skin examinations, according to a report in the January issue of Archives of Dermatology, one of th…
Reston, Va. — A study published in the December issue of The Journal of Nuclear Medicine identified positron emission tomography/computed tomography (PET/CT) scans as a potentially useful tool for predicting local recurrence in lung cancer patien…
A new study has found that women who receive silicone implants after a double mastectomy are more satisfied with their breasts than women who receive saline implants. Published early online in CANCER, a peer-reviewed journal of the American Cancer S…
FOR EMBARGOED RELEASE:
October 25, 2010 12:01AM ET
New Way of Expanding Cancer Screening for Minority Women
New York, October 25, 2010 — Minority patients have a significantly decreased survival from colon ca…
Offering colorectal cancer screening to poor minority women during mammography visits can effectively expand screening in this otherwise underserved population, although lack of medical insurance remains a significant barrier. That is the conclusion…
NEW YORK, September 14, 2010 — A blood test at the age of 60 can accurately predict the risk that a man will die from prostate cancer within the next 25 years, according to researchers at Memorial Sloan-Kettering Cancer Center, in New York, and Lun…
The options for treating advanced melanoma are limited – regardless of whether the patient is a dog or a human. Because this deadly cancer is virtually resistant to chemotherapy and radiation in its late stages, new approaches are being investigated including vaccines that harness the immune system. For nine dogs that naturally developed canine malignant melanoma, treatment with a new DNA-based vaccine more than tripled their median survival from an expected 90 days to an average of 389 days.
Smoking, the number one cause of preventable death in the United States, causes 130,000 lung cancer deaths each year. Many smokers are now considering screening with low-dose helical computed tomography (CT) scans in the hope of diagnosing the disease early. A new study that shows lung cancer risk varies widely among smokers may help individuals and their doctors decide if voluntary screening is appropriate for them.
Researchers have developed a novel approach to genetically instruct human immune cells to recognize and kill cancer cells in a mouse model. The investigators plan to ultimately apply this strategy in a clinical trial setting for patients with certain forms of leukemias and lymphomas. Scientists at Memorial Sloan-Kettering Cancer Center (MSKCC) genetically engineered an antigen receptor, introduced it into cultured human T cells, and infused the T cells in mice that bear widespread tumor cells. The modified T cells, now able to recognize the targeted antigen present on the tumor cells, eradicated the cancer.
A rare genetic syndrome, Dyskeratosis Congenita (DC), may hold the key to understanding a mechanism that causes premature aging and cancer. Recreating DC in genetically altered knockout mice, researchers at Memorial Sloan-Kettering Cancer Center and colleagues proved that the disorder was caused, as theorized, by mutations in the DKC1 gene. Unexpectedly, they also showed that DC was caused by a disruption in ribosome function and not due to shortened telomeres (the distal end of a chromosome arm) as previously hypothesized. Their results, published in the January 10 issue of Science, may have implications for development of drugs that kill cancer cells by specifically targeting ribosomes, similar to the way ribosome targets have been key to the development of antibiotics for specific bacterial infections.